DNCE

Aerami Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of severe respiratory and other chronic diseases through inhaled medicines. The company utilizes its proprietary Afina™ inhalation platform, a smart, mesh nebulizer technology designed to deliver deep-lung deposition of therapeutics with high precision and ease of use. Aerami's lead candidate, AER-901, is an inhaled formulation of imatinib currently in Phase 2 development for pulmonary arterial hypertension (PAH). The company was originally founded as Dance Biopharm, focusing on inhaled insulin, before rebranding to reflect its broader focus on respiratory and systemic diseases.